Related Experiment Video
Updated: Apr 11, 2026
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
A novel linear neutralizing epitope of hepatitis E virus
Zi-Min Tang1, Ming Tang2, Min Zhao2
1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian 361005, PR China.
Researchers discovered a new Hepatitis E virus (HEV) linear epitope (L2) that elicits a neutralizing antibody response. This finding offers a promising avenue for developing effective HEV vaccines.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Hepatitis E virus (HEV) poses a significant global health challenge, causing acute hepatitis via fecal-oral transmission.
- Current anti-HEV antibody responses target conformational epitopes on pORF2 (a.a. 459-606), crucial for neutralization.
- Identifying linear neutralizing epitopes is key for advancing HEV vaccine development.
Purpose of the Study:
- To identify novel linear neutralizing epitopes of the Hepatitis E virus (HEV).
- To evaluate the immunogenicity and protective efficacy of a newly identified linear epitope (L2) in preclinical models.
Main Methods:
- Screening for neutralizing monoclonal antibody (MAb)-recognized linear epitopes within HEV pORF2.
- Characterization of a novel linear epitope (L2) located at a.a. 423-437, assessing its immunodominance.
- Utilizing hepatitis B virus core protein (HBc) as a carrier to display the L2 epitope.
- Inducing immune responses in mice and assessing protection against HEV infection in rhesus monkeys.
Main Results:
- A novel neutralizing linear epitope (L2) in HEV pORF2 (a.a. 423-437) was identified.
- Epitope L2 was found to be non-immunodominant during natural HEV infection.
- Displaying L2 on an HBc carrier successfully induced HEV-neutralizing antibodies in mice.
- This approach demonstrated protection against HEV challenge in rhesus monkeys.
Conclusions:
- A novel, non-immunodominant linear neutralizing epitope of HEV has been discovered.
- The HBc-displayed L2 epitope can elicit a protective immune response against HEV infection.
- This research provides valuable insights for the development of next-generation HEV vaccines.
More Related Videos
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
01:25Hepatitis
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...